has been cited by the following article(s):
|
[1]
|
Factors influencing methotrexate pharmacokinetics highlight the need for individualized dose adjustment: a systematic review
European Journal of Clinical Pharmacology,
2024
DOI:10.1007/s00228-023-03579-0
|
|
|
|
|
[2]
|
A population pharmacokinetic model of methotrexate in Korean patients with haematologic malignancy
British Journal of Clinical Pharmacology,
2024
DOI:10.1111/bcp.15969
|
|
|
|
|
[3]
|
Insights from a pharmacometric analysis of HDMTX in adults with cancer: Clinically relevant covariates for application in precision dosing
British Journal of Clinical Pharmacology,
2023
DOI:10.1111/bcp.15506
|
|
|
|
|
[4]
|
Insights from a pharmacometric analysis of HDMTX in adults with cancer: Clinically relevant covariates for application in precision dosing
British Journal of Clinical Pharmacology,
2022
DOI:10.1111/bcp.15506
|
|
|
|
|
[5]
|
Evaluation of body-surface-area adjusted dosing of high-dose methotrexate by population pharmacokinetics in a large cohort of cancer patients
BMC Cancer,
2021
DOI:10.1186/s12885-021-08443-x
|
|
|
|
|
[6]
|
Population pharmacokinetics of high‐dose methotrexate in Chinese pediatric patients with medulloblastoma
Biopharmaceutics & Drug Disposition,
2020
DOI:10.1002/bdd.2221
|
|
|
|
|
[7]
|
Population pharmacokinetics of high‐dose methotrexate in Chinese pediatric patients with medulloblastoma
Biopharmaceutics & Drug Disposition,
2020
DOI:10.1002/bdd.2221
|
|
|
|
|
[8]
|
Population Pharmacokinetics of High-Dose Methotrexate in Patients With Primary Central Nervous System Lymphoma
Journal of Pharmaceutical Sciences,
2018
DOI:10.1016/j.xphs.2018.01.004
|
|
|
|
|
[9]
|
Simultaneous determination of plasma methotrexate and 7-hydroxy methotrexate by UHPLC–MS/MS in patients receiving high-dose methotrexate therapy
Journal of Pharmaceutical and Biomedical Analysis,
2018
DOI:10.1016/j.jpba.2018.06.011
|
|
|
|